Table 3 Adverse drug reactions of chemotherapy regimens
ADR | Chemotherapy regimens | P-Value* | |||||||
|---|---|---|---|---|---|---|---|---|---|
FOLOFOX | FOLFIRI | Capecitabine + Cetuximab | Capecitabine | FOLOFOX + Irinotecan | 5-FU | Total | |||
Diarrhea | Exist | 39 (23.6%) | 14 (29.8%) | 0 | 1 (16.7%) | 2 (40%) | 0 (0%) | 56 (24.7%) | 0.39 |
Absent | 126 (76.4%) | 33 (70.2%) | 3 (100%) | 5 (83.3%) | 3 (60%) | 1 (100%) | 171 (75.3%) | ||
Total | 165 | 47 | 3 | 6 | 5 | 1 | 227 | ||
Nausea | Exist | 48 (29.1%) | 14 (29.8%) | 2 (66.7%) | 2 (33.3%) | 3 (60%) | 1 (100%) | 70 (30.8%) | 0.93 |
Absent | 117 (70.95%) | 33 (70.25%) | 1 (33.3%) | 4 (66.7%) | 2 (40%) | 0 (0%) | 157 (69.2%) | ||
Total | 165 | 47 | 3 | 6 | 5 | 1 | 227 | ||
Vomiting | Exist | 28 (17%) | 9 (19.1%) | 1 (33.3%) | 2 (33.3%) | 3 (60%) | 1 (100%) | 44 (19.4%) | 0.73 |
Absent | 137 (83%) | 38 (80.9%) | 2 (66.7%) | 4 (66.7%) | 2 (40%) | 0 (0%) | 183 (80.6%) | ||
Total | 165 | 47 | 3 | 6 | 5 | 1 | 227 | ||
Oral mucositis | Exist | 55 (33.3%) | 18 (38.3%) | 0 (0%) | 2 (33.3%) | 2 (60%) | 1 (100%) | 78 (34.4%) | 0.53 |
Absent | 110 (66.7%) | 29 (61.7%) | 3 (100%) | 4 (66.7%) | 3 (40%) | 0 (0%) | 149 (65.6%) | ||
Total | 165 | 47 | 3 | 6 | 5 | 1 | 227 | ||
Peripheral neuropathy | Exist | 159 (96.4%) | 36 (76.6%) | 3 (100%) | 5 (83.3%) | 5 (100%) | 1 (100%) | 209 (92.1%) | < 0.001 |
Absent | 6 (3.6%) | 11 (23.4%) | 0 (0%) | 1 (16.7%) | 0 (0%) | 0 (0%) | 18 (7.9%) | ||
Total | 165 | 47 | 3 | 6 | 5 | 1 | 227 | ||
Hair loss | Exist | 56 (40%) | 24 (58.5%) | 2 (66.7%) | 5 (83.3%) | 3 (75%) | 1 (100%) | 91 (46.7%) | 0.04 |
Absent | 84 (60%) | 17 (41.2%) | 1 (33.3%) | 1 (16.7%) | 1 (25%) | 0 (0%) | 104 (53.3%) | ||
Total | 140 | 41 | 3 | 6 | 4 | 1 | 195 | ||